Hookipa Pharma's Cancer Immunotherapy Shows T-Cell Response, Interim Efficacy in Pretreated HPV16+ Cancer Settings

Hookipa Pharma Inc HOOK reported positive Phase 1 data from its ongoing Phase 1/2 study evaluating HB-200 to treat advanced Human Papillomavirus 16-positive (HPV16+) cancers.
Data were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
At baseline, all patients had nearly undetectable levels of tumor-specific T cells. Within two weeks of a single dose of HB-200, all patients showed increased tumor-specific CD8+ T cell levels.
As of the data cut-off, (14/15 patients) had target lesion control, including 53% (8/15 patients) with target lesion reduction.
Two of the 14 patients progressed at other sites, resulting in an overall disease control rate of 80 % (12/15 patients).
HB-201 monotherapy demonstrated an 18% overall response rate and an ongoing 3.45-month median progression-free survival.
In addition, HB-201 showed a 73% (8/11 patients) disease control rate, with two partial responses and six patients with stable disease, including four with stable disease for more than 16 weeks.
Preliminary data on HB-201/HB-202 showed a disease control rate of 100 (4/4 patients).
Treatment-related adverse events were reported in 53% of patients.
No serious adverse events, dose-limiting toxicities, and treatment-related adverse events rated grade 3, or higher were reported.
The company expects to start registration enabling in 2022.
Price Action: HOOK shares are up 7.77% at $14.28 during the premarket session on the last check Tuesday.